Congress Takes Action To Reduce U.S. Reliance On Chinese Drugs

Source: National Interest - View Original Article
Published: May 04, 2020
Category:
Bias Rating:

76% Conservative


Bias Score Calculation:


Policies:

Protectionist Trade

Sentiments

97% "As this pandemic is showing us, shortages cause problems, including higher death rates.""
93% "This is the most advanced clinical candidate for vaccines today.""
89% "Part of this information is already available with the Food and Drug Administration (FDA).""
81% "It is quite likely that Chuck Grassley, Chairman of the Finance Committee, would ultimately create his own bill and potentially take parts of bills ..."
76% "Nationalization and protectionism is very shortsighted.""
75% "Restores Buy American Act's intent for DoD and Department of Veterans Affairs (VA) purchases""
73% "While these may just be merely messaging bills -- Rubio in particular got out in front of the pandemic and essentially was one of ..."
65% "Grassley has long been a China hawk, and has repeatedly called into question our reliance on China for pharmaceuticals.""
63% "I will continue to return to these broader issues in future blogs.""

We have listed the top 10 sentiments. More sentiments do exist. Please review the full article for more information.



*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization

Extremely
Liberal

Very
Liberal

Moderate-left

Neutral

Moderate-right

Very
Conservative

Extremely
Conservative

100%

100%

Contributing sentiments towards policy:

97% : As this pandemic is showing us, shortages cause problems, including higher death rates.
93% : This is the most advanced clinical candidate for vaccines today.
89% : Part of this information is already available with the Food and Drug Administration (FDA).
81% : It is quite likely that Chuck Grassley, Chairman of the Finance Committee, would ultimately create his own bill and potentially take parts of bills when Congress returns.
76% : Nationalization and protectionism is very shortsighted.
75% : Restores Buy American Act's intent for DoD and Department of Veterans Affairs (VA) purchases
73% : While these may just be merely messaging bills -- Rubio in particular got out in front of the pandemic and essentially was one of the lead authors of the Paycheck Protection Program -- they may well lead to anti-China drug policy in the near future.
65% : Grassley has long been a China hawk, and has repeatedly called into question our reliance on China for pharmaceuticals.
63% : This needs to change.
63% : I will continue to return to these broader issues in future blogs.
62% : The FDA already knows the location of manufacture and any change to the location or the process requires the manufacturer to file a Type II variation.
62% : The Drug Shortages Task Force can use this to project upcoming shortages.
60% : Marco Rubio (R-FL) and a group of bipartisan senators (including Elizabeth Warren (D-MA)) is promoting a bill which would limit US reliance on drugs and drug ingredients coming from China.
60% : More generally, China may be the concern when it comes to national security, but India and other nations where drug manufacturing is done do not live up to western standards.
59% : The problem is that the FDA does not disclose this -- despite the Freedom of Information Act (FOIA) agency requests -- because it considers this information "proprietary".
59% : This is a good idea in principle.
58% : These senators view reliance on China as a national security threat.
58% : But then what?
56% : While we would never rely on China for traditional security apparatus, we have been happy to allow China to provide the basis of our pharmaceuticals.
55% : This leads to all sorts of quality problems and can drive shortages.
54% : Requires drug makers to provide the Food and Drug Administration (FDA) with information to determine volume of APIs used in pharmaceuticals.
53% : Currently, both bills are referred to the Senate Finance committee, and neither Rubio nor Cotton are on this committee.
51% : So what are some of the specifics?
51% : The bill also would prohibit federal agencies and health facilities from purchasing APIs and other pharmaceutical products manufactured in China without an FDA waiver certifying that China is the sole source.
49% : By adding this clause to the legislation, we will be twisting ourselves into a pretzel if that candidate succeeds in clinical studies, depriving the VA of the vaccine, which will require us to go back and amend the law (if this bill were to eventually pass).
46% : They have a point.
46% : That way, even if one of these locations is in China, we have a back up.
34% : Direct the Department of Defense (DoD) to determine the extent of its dependency on foreign entities for drugs, active pharmaceutical ingredients (API), and pharmaceutical components.
29% : A less significant bill (because it is not bipartisan) is being promoted by Tom Cotton (R-AR) and Ted Cruz (R-TX).
26% : It would be helpful if this bill mandated that the manufacturer must disclose the location of manufacturer of the specific batch of the product on the label so that pharmacists on down know where the product is actually made.
25% : Oxford (Jenner Institute) is in advanced stages with a vaccine candidate for COVID-19 which will be manufactured at the Serum Institute in Pune, India.
24% : Additionally, DoD would be required to determine whether this creates a national security issue and to make recommendations to eliminate US dependency on foreign sources.
24% : The FDA needs to tell us where the source of the API and the Finished Dosage formulation is.
24% : Here is an example.
21% : In essence, this would require the FDA to establish a registry to track APIs and institute a country-of-origin label for imported drugs.
20% : We should mandate a risk-mitigation strategy where any drug that is on the "national list of essential medicines" has at least two sources of API/dosage, not in the same geography.
17% : The bill would provide economic incentives for producing pharmaceuticals and medical equipment in the United States.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization

Share via
Copy link
Powered by Social Snap